Tech Stock News
Thursday, March 23, 2023
Adamis Pharmaceuticals Corp (NASDAQ: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged for appraisal the company’s resubmitted New Drug Application (NDA) for ZIMHI™. FDA finishes filing appraisal and governs NDA adequately ample for fundamental appraisal Adamis has received FDA communication involving the company’s NDA, affirming […]
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) dropped 1.96% after the company announced that start-up activities for the clinical trial of its experimental COVID-19 treatment, Tempol, are underway. The company is conducting the activities in collaboration with an extensive clinical research organization. Adamis commence activities on a COVID-19 treatment study Already, site […]